DNLI: Denali Therapeutics Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 2,819.42
Enterprise Value ($M) 2,728.79
Book Value ($M) 1,318.49
Book Value / Share 9.16
Price / Book 2.14
NCAV ($M) 733.32
NCAV / Share 5.10
Price / NCAV 3.84

Profitability (mra)
Return on Invested Capital (ROIC) -0.31
Return on Assets (ROA) -0.37
Return on Equity (ROE) -0.41

Liquidity (mrq)
Quick Ratio 9.98
Current Ratio 9.98

Balance Sheet (mrq) ($M)
Current Assets 868.84
Assets 1,454.01
Liabilities 135.52
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-12 13G/A Fmr Llc 7.08 41.02
11-12 13G Capital Research Global Investors 5.50
11-08 13G/A Wellington Management Group Llp 7.49 47.46
11-08 13G/A BlackRock, Inc. 9.60 0.00
11-07 13G/A Biogen Inc. 4.97 -43.89
02-13 13G/A Bratton Douglas K 4.20 -17.85
02-13 13G/A Vanguard Group Inc 7.84 8.92
01-30 13G/A Temasek Holdings (Private) Ltd 4.90 0.00
01-30 13G/A Baillie Gifford & Co 10.32 -5.68

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 185,098 1,445,132 12.81
2025-01-14 109,072 763,958 14.28
2025-01-13 69,172 689,264 10.04
2025-01-10 237,845 1,157,605 20.55

(click for more detail)

Similar Companies
CTMX – CytomX Therapeutics, Inc. CYTK – Cytokinetics, Incorporated
DAWN – Day One Biopharmaceuticals, Inc. DSGN – Design Therapeutics, Inc.
DVAX – Dynavax Technologies Corporation


Financial data and stock pages provided by
Fintel.io